Lv5
920 积分 2024-08-18 加入
[Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2026 edition)]
1个月前
已完结
Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
4个月前
已完结
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
5个月前
已完结
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
5个月前
已完结
The safety, tolerability, and efficacy of BRY812 in patients with advanced solid tumors: Preliminary results from the phase I clinical study
6个月前
已关闭
Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
6个月前
已完结
259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
6个月前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
8个月前
已完结
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma
9个月前
已完结
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
9个月前
已完结
皖公网安备34019202002308
